Puma Biotechnology (PBYI) PT Lowered to $87 at Stifel
Get Alerts PBYI Hot Sheet
Rating Summary:
5 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 14 | New: 17
Join SI Premium – FREE
Stifel lowered its price target on Puma Biotechnology (NASDAQ: PBYI) to $87.00 (from $95.00) while maintaining a Buy rating.
Analyst Alex Schwartz commented, "Yesterday Puma reported 1Q18 numbers that included $66.5 million in revenue and a $24.3 million net loss. Nerlynx revenues of $36.0 million were below our $42.1 million estimates but in-line with $36 million consensus estimates. As part of the release, management indicated they now expect NALA data during 4Q18/2019 (versus prior 2Q18 expectations) due to slower than expected event rate. As a result, we are pushing out our metastatic revenue estimates by a year. Accordingly, our target price decreases from $95 to $87. Despite our reduction in target price, we remain positive on the stock due to a reasonable chance at positive metastatic breast cancer data (NCCN already recommends Nerlynx to BC patients with brain metastases) and Nerlynx extended adjuvant EMA re-examination success."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cleveland Research Upgrades Dynatrace Inc. (DT) to Buy, 'optimism underlying fundamentals are likely to support upside'
- Torrent Pharma (TRP:IN) PT Raised to INR2,960 at HSBC
- IDP Education (IEL:AU) (IDPUF) PT Lowered to AUD17.60 at JPMorgan
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT ChangeRelated Entities
StifelSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!